Atwood & Palmer Inc. Has $42.94 Million Holdings in Gilead Sciences, Inc. $GILD

Atwood & Palmer Inc. lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 349,835 shares of the biopharmaceutical company’s stock after buying an additional 5,685 shares during the quarter. Gilead Sciences comprises about 2.4% of Atwood & Palmer Inc.’s holdings, making the stock its 11th largest position. Atwood & Palmer Inc.’s holdings in Gilead Sciences were worth $42,939,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Invesco Ltd. boosted its stake in Gilead Sciences by 12.0% during the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after acquiring an additional 1,618,453 shares in the last quarter. Legal & General Group Plc boosted its stake in Gilead Sciences by 4.2% during the third quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock worth $1,133,376,000 after acquiring an additional 414,454 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in Gilead Sciences by 5.9% during the third quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock worth $793,506,000 after acquiring an additional 400,002 shares in the last quarter. Nordea Investment Management AB boosted its stake in Gilead Sciences by 16.5% during the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock worth $630,056,000 after acquiring an additional 726,101 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after acquiring an additional 4,113,999 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Mizuho increased their target price on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. Wells Fargo & Company increased their target price on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Bank of America set a $162.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Oppenheimer increased their target price on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. Finally, The Goldman Sachs Group increased their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $157.35.

Gilead Sciences Stock Up 0.6%

Gilead Sciences stock opened at $133.64 on Friday. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29. The firm has a market capitalization of $165.88 billion, a price-to-earnings ratio of 19.74, a price-to-earnings-growth ratio of 1.76 and a beta of 0.39. The firm’s fifty day moving average price is $142.93 and its two-hundred day moving average price is $131.90. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same period last year, the firm earned $1.90 earnings per share. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post 8.63 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. Gilead Sciences’s payout ratio is 48.45%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the transaction, the chief financial officer directly owned 176,191 shares of the company’s stock, valued at approximately $24,835,883.36. This trade represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the completion of the transaction, the chief executive officer directly owned 613,912 shares in the company, valued at $92,086,800. This trade represents a 15.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 178,640 shares of company stock valued at $26,691,550. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.